-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Knight Therapeutics, Raises Price Target to C$13

Benzinga·11/06/2026 19:52:26
Listen to the news
RBC Capital analyst Douglas Miehm maintains Knight Therapeutics (TSX:GUD) with a Outperform and raises the price target from C$11 to C$13.